Duration of immunosuppressive treatment for chronic graft-versus-host disease.
暂无分享,去创建一个
R. Storb | B. Storer | F. Appelbaum | M. Flowers | J. Hansen | H. Kiem | E. Petersdorf | C. Anasetti | Paul J. Martin | J. Storek | R. Nash | H. Deeg | J. Sanders | P. Carpenter | C. Moravec | B. Stewart | A. Morton | P. Martin
[1] F. Appelbaum,et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.
[2] Stephanie J. Lee,et al. An update on how to treat chronic GVHD. , 2003, Blood.
[3] Je-Hwan Lee,et al. Graft‐versus‐host disease (GVHD)‐specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation , 2003, British journal of haematology.
[4] Stephanie J. Lee,et al. Re: chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] J. Lynch,et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. , 2003, Blood.
[6] M. MacMillan,et al. Chronic graft-versus-host disease: a prospective cohort study. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] P. Ljungman,et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] S. Iacobelli,et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. , 2002, Blood.
[9] John P Klein,et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.
[10] R. Storb,et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.
[11] H. Deeg,et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.
[12] K. Sullivan,et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] C Anasetti,et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.
[14] D. Paniagua,et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Storb,et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. , 2001, Blood.
[16] K. Horibe,et al. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children , 2001, Bone Marrow Transplantation.
[17] H. Deeg,et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.
[18] J. V. Stone,et al. Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .
[19] J. V. Stone,et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. , 1999, The New England journal of medicine.
[20] P. Ljungman,et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis , 1998, Bone Marrow Transplantation.
[21] A. Tichelli,et al. Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation , 1997, Annals of Internal Medicine.
[22] D. Weisdorf,et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. , 1994, Bone marrow transplantation.
[23] M. Pepe,et al. Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods , 1993, British journal of haematology.
[24] A. Rimm,et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.
[25] O. Ringdén,et al. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors--acute graft-versus-host disease, and splenectomy. , 1990, Transplantation.
[26] S. Piantadosi,et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. , 1989, Blood.
[27] Jean E. Sanders,et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.
[28] H. Deeg,et al. Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation , 2005 .
[29] L. VázquezSell,et al. Graft-versus-host disease. , 1991, The New England journal of medicine.
[30] H. Deeg,et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. , 1983, Annals of internal medicine.
[31] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[32] A. Kumagai. [Glucocorticoid therapy]. , 1969, Jibi inkoka Otolaryngology.